Grant of Share Options & PDMR Dealings
No summary for this filing – the full text is below.
Select text to share a quote on X · sign in to keep highlights & notes in your GENI notes
GENinCode Plc (AIM: GENI), the genetics company focused on the prevention of cardiovascular disease and ovarian cancer, announces that on 21 March 2025 the Company approved the grant of options over an aggregate of 14,028,305 new ordinary shares of 1 pence each in the Company ('Ordinary Shares') under the 2021 Share Option Plan ('2021 Share Option Plan') to certain directors and employees of the Company (the "New Options"), representing 4.89% per cent. of the Company's existing issued share capital.
Terms of the New Options
The Company adopted the 2021 Share Option Plan to enable it to retain and incentivise staff and to reward them for the achievement of its longer-term objectives. 14,028,305 New Options will be issued at an exercise price of 3.7 pence per share which are exercisable on the second anniversary of the date of grant. There are no other vesting criteria for the New Options which have a 10-year term.
Details of resultant holdings
Following the New Options grant and the Option Surrender, details of Options held by Directors, PDMRs and other employees of the Company, are as follows:
| Director's name | Position | Number of New Options granted at 3.7 pence | Aggregate number of options post grant | Current total beneficial holding of Ordinary Shares | Current holding as a % of Issued share capital |
|---|---|---|---|---|---|
| Matthew Walls | CEO | 2,431,082 | 5,254,832 | 12,235,473 | 4.26% |
| Paul Foulger | CFO | 2,216,062 | 4,790,062 | 1,273,587 | 0.44% |
| Jordi Puig | COO | 1,462,524 | 3,161,274 | 14,737,636 | 5.14% |
| William Rhodes | Non-Executive Chair | 554,016 | 1,197,516 | - | 0.0% |
| Huon Gray | Non-Executive Director | 387,423 | 837,423 | 905,405 | 0.32% |
| Felix Frueh | Non-Executive Director | 387,423 | 837,423 | 100,000 | 0.03% |
| Sergio Olivero | Non-Executive Director | 172,188 | 172,188 | 7,417,243 | 2.59% |
| Other Employees | 6,417,587 | 16,912,905 | N/A | N/A | |
| Total: | 12,640,526 | 32,991,435 | 36,669,344 | 12.78% |
Following the grant of the New Options, there are Options over a total of 32,915,560 Ordinary Shares in the Company as at the date of this announcement, representing approximately 11.47% of the Company's existing issued share capital.
Giles Balleny /Dan Hodkinson (Corporate Finance) Dale Bellis / Michael Johnson (Sales) Nigel Birks (Life Sciences Specialist Sales) Ondraya Swanson (Corporate Broking)
| Walbrook PR Limited Anna Dunphy / Paul McManus / Louis Ashe-Jepson | Tel: 020 7933 8780 or genincode@walbrookpr.com | ||
|---|---|---|---|
| 2 | Reason for notification | ||
| a. | Position/Status | 1. Chief Executive Officer 2. Chief Financial Officer 3. Chief Operating Officer 4. N on-Executive Chair 5. Non-Executive Director 6. Non-Executive Director 7. Non-Executive Director | |
| b. | Initial notification/ Amendment | Initial Notification | |
| a. | Name | GENinCode Plc | |
| b. | LEI | 213800UX6TE7K65O2892 | |
| a. | Description of the financial instrument, type of instrument Identification Code | Options over Ordinary Shares of 1p each N/A | |
| b. | Nature of the transaction | Grant of options under the 2021 Share Option Plan with time vesting conditions attached | |
| c. | Price(s) and volume(s) | Exercise Price(s) | Volume(s) |
| 1. | 3 .7 pence | 2,431,082 | |
| 2. | 3 .7 pence | 2,216,062 | |
| 3. | 3 .7 pence | 1,462,524 | |
| 4. | 3 .7 pence | 554,016 | |
| 5. | 3 .7 pence | 387,423 | |
| 6. | 3 .7 pence | 387,423 | |
| 7 . | 3.7 pence | 172,188 | |
| d. | Aggregated information - Aggregated Volume - Price | See above | |
| f. | Place of the transaction | Outside a trading venue |
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.